MGC Pharmaceuticals Completes glioblastoma study
- MGC Pharmaceuticals (MXC) completes a successful in-vitro preclinical research study in the use of cannabinoids to treat glioblastoma
- The study was undertaken between 2019 and 2022, initially using a formulation that included THC but was later replaced with cannabigerol (CBG)
- Over 5800 cell tests were collected from 18 patients to determine the most effective concentrations and ratios of cannabidiol (CBD) and CBG in treatment
- The results demonstrated the efficacy of cannabinoids in the treatment of glioblastoma and determined the most effective CBD:CBG ratio
- MGC Pharma ends the day 35.3 per cent in the green with shares trading at 2.3 cents
